source
- CG Oncology reports 68% drop in bladder cancer recurrence in phase 3 trial of cretostimogeneCG Oncology announced results from a phase 3 study of its oncolytic virus immunotherapy, cretostimogene, in patients with non-muscle invasive bladder cancer after surgery. The trial, involving 367…
- Flagship Pioneering invests £100 million to launch AI-focused biotech incubation lab in LondonFlagship Pioneering announced a £100 million investment to establish its first AI-focused biotech incubation unit outside Cambridge, locating it in London. The new Flagship Origination Lab, U.K.,…